Hepat Oncol 7(2): HEP22

Recent advances of GOLM1 in hepatocellular carcinoma

^{Department of Liver Surgery & Transplantation, Liver Cancer Institute & Zhongshan Hospital, Fudan University, Shanghai, 200032, China}

^{Key Laboratory of Carcinogenesis & Cancer Invasion (Fudan University), Ministry of Education, Fudan University, Shanghai, 200032, China}

^{Author for correspondence:}nc.hs.latipsoh-sz@iahgniq.ey

^{Authors contributed equally}

Received 2020 Feb 23; Accepted 2020 May 21.

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License

Abstract

Hepatocellular carcinoma (HCC) is one of the most common liver malignancies and is a leading cause of cancer-related deaths. Most HCC patients are diagnosed at an advanced stage and current treatments show poor therapeutic efficacy. It is particularly urgent to explore early diagnosis methods and effective treatments of HCC. There are a growing number of studies that show GOLM1 is one of the most promising markers for early diagnosis and prognosis of HCC. It is also involved in immune regulation, activation and degradation of intracellular signaling factors and promotion of epithelial–mesenchymal transition. GOLM1 can promote HCC progression and metastasis. The understanding of the GOLM1 regulation mechanism may provide new ideas for the diagnosis, monitoring and treatment of HCC.

Keywords: : diagnosis, GOLM1, hepatocellular carcinoma, immune system, prognosis

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide [1]. The poor prognosis is due to extensive regional invasion and distant metastases at the time of diagnosis. Therefore, it is necessary to explore effective early diagnosis and identify reliable biological and clinical markers. The relationship between Golgi apparatus and tumors is receiving growing attention [2,3]. New Golgi proteins and Golgi-related proteins have been discovered. Among them, GOLM1 (also known as GP73 or GOLPH2) is the most anticipated tumor biomarker. A growing number of studies have shown that the abnormal expression of GOLM1 is associated with HCC and may become a new target for the prevention, monitoring and treatment of HCC [4–7]. In this review, we discuss the recent advances of GOLM1 in HCC and present an overall view of future research.

Footnotes

Author contributions

J Yan and B Zhou consulted the literature, analyzed the data, summarized and wrote the manuscript. H Li and L Guo analyzed the literature data and revised the manuscript. Q Ye supervised the design of this review, analyzed the literature data, made a summary and revised the manuscript. All authors approved the final version of the manuscript.

Financial & competing interests disclosure

This work was supported in part by the Program of Shanghai Subject Chief Scientist (no. 16XD1400800) and the National Natural Science Foundation of China (no. 81572301, 81502487, 81802893 and 81871924). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Open access

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

References

1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet391(10127), 1301–1314 (2018). [[PubMed]
2. Li H, Zhang P, Luo J. et al. Chondroitin sulfate-linked prodrug nanoparticles target the Golgi apparatus for cancer metastasis treatment. ACS Nano13(8), 9386–9396 (2019). [[PubMed]
3. Yu RY, Xing L, Cui PF. et al. Regulating the Golgi apparatus by co-delivery of a COX-2 inhibitor and brefeldin A for suppression of tumor metastasis. Biomater. Sci.6(8), 2144–2155 (2018). [[PubMed]
4. Sai WL, Yao M, Shen SJ. et al. Dynamic expression of hepatic GP73 mRNA and protein and circulating GP73 during hepatocytes malignant transformation. Hepatobiliary Pancreat. Dis. Int. (2020) (Epub ahead of print). [[PubMed]
5. Liu Y, Zhou S, Shi J. et al. c-Myc transactivates GP73 and promotes metastasis of hepatocellular carcinoma cells through GP73-mediated MMP-7 trafficking in a mildly hypoxic microenvironment. Oncogenesis8(10), 58 (2019).
6. Gai X, Tang B, Liu F. et al. mTOR/miR-145-regulated exosomal GOLM1 promotes hepatocellular carcinoma through augmented GSK-3beta/MMPs. J. Genet. Genomics46(5), 235–245 (2019). [[PubMed]
7. Ke MY, Wu XN, Zhang Y, Wang S, Lv Y, Dong J. Serum GP73 predicts posthepatectomy outcomes in patients with hepatocellular carcinoma. J. Transl. Med.17(1), 140 (2019).
8. Kladney RD, Bulla GA, Guo L. et al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene249(1–2), 53–65 (2000). • First report of the isolation and characterization of GOLM1.
9. Zhou Y, Li L, Hu L, Peng T. Golgi phosphoprotein 2 (GOLPH2/GP73/GOLM1) interacts with secretory clusterin. Mol. Biol. Rep.38(3), 1457–1462 (2011). [[PubMed]
10. Xia Y, Zhang Y, Shen M, Xu H, Li Z, He N. Golgi protein 73 and its diagnostic value in liver diseases. Cell Prolif.52(2), e12538 (2019).
11. Ba MC, Long H, Tang YQ, Cui SZ. GP73 expression and its significance in the diagnosis of hepatocellular carcinoma: a review. Int. J. Clin. Exp. Pathol.5(9), 874–881 (2012).
12. Iftikhar R, Kladney RD, Havlioglu N. et al. Disease- and cell-specific expression of GP73 in human liver disease. Am. J. Gastroenterol.99(6), 1087–1095 (2004). [[PubMed]
13. Kladney RD, Tollefson AE, Wold WS, Fimmel CJ. Upregulation of the Golgi protein GP73 by adenovirus infection requires the E1A CtBP interaction domain. Virology301(2), 236–246 (2002). [[PubMed]
14. Puri S, Bachert C, Fimmel CJ, Linstedt AD. Cycling of early Golgi proteins via the cell surface and endosomes upon lumenal pH disruption. Traffic3(9), 641–653 (2002). [[PubMed]
15. Bachert C, Fimmel C, Linstedt AD. Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic8(10), 1415–1423 (2007). [[PubMed]
16. Wright LM, Yong S, Picken MM, Rockey D, Fimmel CJ. Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int. J. Clin. Exp. Pathol.2(1), 34–47 (2009).
17. Shi Y, Chen J, Li L. et al. A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol. Cancer Res. Treat.10(3), 287–294 (2011). [[PubMed]
18. Mao Y, Yang H, Xu H. et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut59(12), 1687–1693 (2010). [•• Demonstrates that GOLM1 is an accurate serum marker for the detection of hepatocellular carcinoma and its recurrence after surgery.[PubMed]
19. Zhou Y, Yin X, Ying J, Zhang B. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer12, 17 (2012).
20. Tian L, Wang Y, Xu D. et al. Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int. J. Cancer129(8), 1923–1931 (2011). [[PubMed]
21. Hu JS, Wu DW, Liang S, Miao XY. GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med. Oncol.27(2), 339–345 (2010). [[PubMed]
22. Marrero JA, Romano PR, Nikolaeva O. et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J. Hepatol.43(6), 1007–1012 (2005). [[PubMed]
23. Zhao Y, Zhang L, Huo L. et al. Clinical significance of fucosylated GP73 in the differential diagnosis of hepatocellular carcinoma. Int. J. Biol. Markers33(4), 439–446 (2018). [[PubMed]
24. Liu T, Yao M, Liu S. et al. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget8(10), 16498–16506 (2017).
25. Yang J, Li J, Dai W. et al. Golgi protein 73 as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. Exp. Ther. Med.9(4), 1413–1420 (2015).
26. Sun Y, Yang H, Mao Y. et al. Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. J. Gastroenterol. Hepatol.26(7), 1207–1212 (2011). [[PubMed]
27. Chen X, Wang Y, Tao J. et al. mTORC1 up-regulates GP73 to promote proliferation and migration of hepatocellular carcinoma cells and growth of xenograft tumors in mice. Gastroenterology149(3), 741–752 e714 (2015). [[PubMed]
28. Dong Y, Zheng Q, Wang Z. et al. Higher matrix stiffness as an independent initiator triggers epithelial–mesenchymal transition and facilitates HCC metastasis. J. Hematol. Oncol.12(1), 112 (2019).
29. Bao YX, Cao Q, Yang Y. et al. Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC). Diagn. Pathol.8, 197 (2013).
30. Yang Y, Liu Q, Zhang H. et al. Silencing of GP73 inhibits invasion and metastasis via suppression of epithelial–mesenchymal transition in hepatocellular carcinoma. Oncol. Rep.37(2), 1182–1188 (2017). [[PubMed]
31. Ye QH, Zhu WW, Zhang JB. et al. GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis. Cancer Cell30(3), 444–458 (2016). •• Reveals the functional role of GOLM1 in EGFR recycling and metastatic progression of hepatocellular carcinoma.
32. Liu Y, Zhang X, Sun T. et al. Knockdown of Golgi phosphoprotein 2 inhibits hepatocellular carcinoma cell proliferation and motility. Oncotarget7(16), 21404–21415 (2016).
33. Jin D, Tao J, Li D. et al. Golgi protein 73 activation of MMP-13 promotes hepatocellular carcinoma cell invasion. Oncotarget6(32), 33523–33533 (2015).
34. Shah M, Huang D, Blick T. et al. An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer. PLoS ONE7(1), e29615 (2012).
35. Osako Y, Seki N, Kita Y. et al. Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma. Int. J. Oncol.49(6), 2255–2264 (2016).
36. Zhang S, Ge W, Zou G. et al. MiR-382 targets GOLM1 to inhibit metastasis of hepatocellular carcinoma and its down-regulation predicts a poor survival. Am. J. Cancer Res.8(1), 120–131 (2018).
37. Zhao J, Xu T, Wang F, Cai W, Chen L. miR-493-5p suppresses hepatocellular carcinoma cell proliferation through targeting GP73. Biomed. Pharmacother.90, 744–751 (2017). [[PubMed]
38. Zhou YY, Jiang JC, You J, Zhou LF. Effect of Golgi phosphoprotein 2 (GOLPH2/GP73) on autophagy in human hepatocellular carcinoma HepG2 cells. Tumour Biol.36(5), 3399–3406 (2015). [[PubMed]
39. Zhang YL, Zhang YC, Han W. et al. Effect of GP73 silencing on proliferation and apoptosis in hepatocellular cancer. World J. Gastroenterol.20(32), 11287–11296 (2014).
40. Zhao N, Guo M, Wang K, Zhang C, Liu X. Identification of pan-cancer prognostic biomarkers through integration of multi-omics data. Front. Bioeng. Biotechnol.8, 268 (2020).
41. Daniele A, Divella R, Quaranta M. et al. Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization. Clin. Biochem.47(3), 184–190 (2014). [[PubMed]
42. Chen MH, Jan YH, Chang PM. et al. Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma. Ann. Surg. Oncol.20(Suppl. 3), S616–S624 (2013). [[PubMed]
43. Riener MO, Stenner F, Liewen H. et al. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology49(5), 1602–1609 (2009). [[PubMed]
44. Hann HW, Wang M, Hafner J. et al. Analysis of GP73 in patients with HCC as a function of anti-cancer treatment. Cancer Biomark.7(6), 269–273 (2010).
45. Mao YL, Yang HY, Xu HF. et al. [Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: a primary study]. Zhonghua Yi Xue Za Zhi88(14), 948–951 (2008). [[PubMed]
46. Ai N, Liu W, Li ZG, Ji H, Li B, Yang G. High expression of GP73 in primary hepatocellular carcinoma and its function in the assessment of transcatheter arterial chemoembolization. Oncol. Lett.14(4), 3953–3958 (2017).
47. Ando E, Kuromatsu R, Tanaka M. et al. Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease. J. Clin. Gastroenterol.40(10), 942–948 (2006). [[PubMed]
48. Shim JH, Yoon DL, Han S. et al. Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis. Ann. Surg. Oncol.19(12), 3687–3696 (2012). [[PubMed]
49. Liang H, Ai-Jun J, Ji-Zong Z. et al. Clinicopathological significance of miR-27b targeting Golgi protein 73 in patients with hepatocellular carcinoma. Anticancer Drugs30(2), 186–194 (2019). [[PubMed]
50. Nishimura T, Iwakabe K, Sekimoto M. et al. Distinct role of antigen-specific T helper Type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med.190(5), 617–627 (1999).
51. Jenner RG, Townsend MJ, Jackson I. et al. The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes. Proc. Natl Acad. Sci. USA106(42), 17876–17881 (2009).
52. Corthay A, Skovseth DK, Lundin KU. et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity22(3), 371–383 (2005). [[PubMed]
53. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer12(4), 265–277 (2012).
54. Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol. Res.2(2), 91–98 (2014). [[PubMed]
55. Tang QF, Ji Q, Tang Y. et al. Golgi phosphoprotein 2 down-regulates the Th1 response in human gastric cancer cells by suppressing IL-12A. Asian Pac. J. Cancer Prev.14(10), 5747–5751 (2013). [[PubMed]
56. Kim HJ, Lv D, Zhang Y, Peng T, Ma X. Golgi phosphoprotein 2 in physiology and in diseases. Cell Biosci.2(1), 31 (2012).
57. Zhang X, Zhu C, Wang T. et al. GP73 represses host innate immune response to promote virus replication by facilitating MAVS and TRAF6 degradation. PLoS Pathog.13(4), e1006321 (2017).
58. Zhang W, Zhang J, Zhang Z. et al. Overexpression of indoleamine 2,3-dioxygenase 1 promotes epithelial-mesenchymal transition by activation of the IL-6/STAT3/PD-L1 pathway in bladder cancer. Transl. Oncol.12(3), 485–492 (2019).
59. Wolfle SJ, Strebovsky J, Bartz H. et al. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur. J. Immunol.41(2), 413–424 (2011). [[PubMed]
60. Song TL, Nairismagi ML, Laurensia Y. et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood132(11), 1146–1158 (2018).
61. Wang Y, Liu T, Huang P. et al. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma. Oncotarget6(15), 13564–13578 (2015).
62. Zhang X, Meng S, Zhang R. et al. GP73-regulated oncolytic adenoviruses possess potent killing effect on human liver cancer stem-like cells. Oncotarget7(20), 29346–29358 (2016).